Literature DB >> 27232106

Detection of erythroblast antibodies in mitogen-stimulated bone marrow cultures from patients with myelodysplastic syndromes.

Anna Zaninoni1, Francesca G Imperiali1, Alessandra Cattaneo2, Giulia Soverini1, Francesca Binda1, Laura Porretti2, Agostino Cortelezzi1,3, Wilma Barcellini1.   

Abstract

BACKGROUND: Low-risk myelodysplastic syndromes (MDS) show several immunologic abnormalities, including increased frequency of autoimmune manifestations and/or overt autoimmune diseases, whose prognostic significance still remains controversial. STUDY DESIGN AND METHODS: We studied the presence of erythroblast antibodies in mitogen-stimulated bone marrow (BM) cultures of 70 patients with early-stage MDS (refractory anemia and refractory anemia with ringed sideroblasts).
RESULTS: Sixty-six percent of patients showed positive erythroblast antibodies, along with BM erythroid hyperplasia and a hemolytic picture in the peripheral blood. Supernatants from positive cultures induced an increase of overall cellularity, the appearance of erythroblastic clustering, and dyserythropoietic signs in normal BM. We identified CD45(dim) Gly-A(dim) CD71(bright) cells (red blood cell precursors at different maturation stage) as the target of the antibodies. Erythropoietin (EPO) levels were reduced and EPO receptors (EPO-R) increased in BM culture supernatants from positive patients. However, flow cytometric analysis showed that neither EPO nor EPO-R was involved in an abnormal stimulation driven by these autoantibodies. Values of the proapoptotic protein Bax were increased in positive patients and Bcl-2 levels were decreased, although not significantly.
CONCLUSION: MDS patients with anti-erythroblast autoimmunity showed increased BM apoptosis, suggesting that the autoimmune reaction may contribute to an unfavorable BM microenvironment for optimal erythropoiesis.
© 2016 AABB.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27232106     DOI: 10.1111/trf.13652

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

1.  Antibodies specific to ferritin light chain polypeptide are frequently detected in patients with immune‑related pancytopenia.

Authors:  Shanfeng Hao; Yang Zhang; Luogang Hua; Ning Xie; Na Xiao; Huaquan Wang; Rong Fu; Zonghong Shao
Journal:  Mol Med Rep       Date:  2020-06-26       Impact factor: 2.952

Review 2.  Immune Phenomena in Myeloid Neoplasms: An "Egg or Chicken" Question.

Authors:  Wilma Barcellini; Bruno Fattizzo
Journal:  Front Immunol       Date:  2021-09-29       Impact factor: 7.561

3.  Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience.

Authors:  Bruno Fattizzo; Giorgia Virginia Levati; Juri Alessandro Giannotta; Giulio Cassanello; Lilla Marcella Cro; Anna Zaninoni; Marzia Barbieri; Giorgio Alberto Croci; Nicoletta Revelli; Wilma Barcellini
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

Review 4.  Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.

Authors:  Bruno Fattizzo; Juri A Giannotta; Wilma Barcellini
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.